## Specification with Markings to Show Changes Made

Please amend the Specification as follows:

On page 12, please replace the title of Example 2 on line 16 with the following:

--EXAMPLE 2: Synthesis and purification of hydrazinopeptide 6 (which includes RGRILKEPVHGV) (SEQ ID NO. 1) (Fig. 2).--

On page 12, please replace the paragraph beginning on line 19 with the following:

Peptide 5 (SEQ ID NO. 5) produced on a Wang resin(0.73 mmol/g, Applied Biosystems, Foster City, USA), using the Fmoc/tert-butyl strategy, as described, for example, by FIELDS et al. in Int. J. Pept. Protein, 1990, 35, 161, and HBTU/Hobt activation (see SCHNÖLZER et al in Int. J. Pept. Protein Res., 1992, 40, 180) using a 431A Applied Biosystem peptide synthesizer (Foster City, USA). Protection of the side chains is provided by: His(Trt), Glu(OtBu), Arg(Pmc), Lys(Boc) (SEQ ID NO. 6). Upon completion of the synthesis, the Fmoc group of the  $\alpha$ -NH<sub>2</sub> function of the arginine is displaced in the presence of 20% piperidine in the DMF. The N, N'-tri(Boc) hydrazinoacetic acid 4 (1.2 eq) is then introduced manually using BOP activation in situ (BOP 1.2 eq, DIEA 3.6 eq in the DMF for 20 minutes), as described, for example, by GAIRI et al. in Tetrahedron Letters, 1990, 50, 7363. Alternatively, N, N'-di(Boc)-hydrazinoacetic acid could also be used. The peptidyl-resin is washed successively with DMF, dichloromethane, and then with ether. is then dried at reduced pressure for 30 minutes.--

On page 16, please replace the header 1) on line 5 with the following:

--1) Synthesis of hydrazinopeptide 19( which includes VGFFKR) (SEQ ID NO. 2)-

On page 16, please replace the header 2) on line 29 with the following:

--2) Synthesis of <u>lipopeptide 21(which includes KVGFFKR) (SEQ ID</u> NO. 3)-

On page 17, please replace the header 1) on line 3 with the following:

--1) Synthesis of hydrazinopeptide 22 (which includes AKFEVNNPQVQRQAFNELIRVVHQLLPESSLRKRKRSR) (SEQ ID NO. 4).

On page 17, please replace the paragraph beginning on line 4 with the following:

Peptide  $\underline{22}$  is prepared on a Fmoc-PAL-PEG-PS resin (0.16 mmol/g, Perseptive) according to the Fmoc/tert-butyl strategy and an HBTU/HOBt activation (see example 2) on a Pioneer-Perseptive peptide synthesizer. Protection for the side chains of the amino acids is as follows: His(Trt), Asn(Trt), Glu(O<sup>t</sup>Bu), Arg(Pbf), Lys(Boc), Ser(<sup>t</sup>Bu)(SEQ ID NO. 7). Upon completion of synthesis, the Fmoc group of the  $\alpha$ -NH<sub>2</sub> function of the alanine is removed in the presence of piperadine at 20% in the DMF. The N,N'-tri(Boc)hydrazinoacetic acid (1.2 eq.) is then introduced manually using BOP activation in situ (BOP: 1.2 eq., DIEA: 3.6 eq. In the DMF for 20 minutes). The peptidyl-resin is washed successively with DMF, dichloromethane, and then ether. It is then dried at reduced pressure for 30 minutes. Cleavage of the peptide-resin link as well as deprotection of the side chains

are carried out in the presence of a TFA/phenol/ethanedithiol/thioanisole/H<sub>2</sub>O mixture (1 g of dry resin/10 ml of TFA/ 0.25 ml of ethanedithiol/0.25 ml of H<sub>2</sub>O/0.25 ml of thioanisole/0.75 g of phenol) with stirring for 3h30 at ambient temperature. The peptide is precipitated in 200 ml of an Et<sub>2</sub>O/heptane mixture (1/1) previously cooled down to 0°C. The precipitate is centrifuged and then dissolved in an H<sub>2</sub>O/AcOH mixture (5/1), deep frozen and freeze dried, 263 mg of raw peptide are obtained from 0.072 mmole of resin.—

Please replace the second paragraph on page 18 starting at line 8 with the following:

--Peptide  $\underline{22}$  and lipopeptide  $\underline{23}$  were prepared as indicated in example 6. Peptide  $\underline{22Sc}$  ("scramble" version of peptide  $\underline{22}$ ) has the following sequence:  $H_2N-NH-CH_2CO-$ 

PSRENQNAVKIQKLSVVLRREQKHRVERLAFRNQSLPF-NH2 (SEQ ID NO. 8).-